# POLEM (NCT03827044)

> Avelumab Plus 5-FU Based Chemotherapy as Adjuvant Treatment for Stage 3 MSI-High or POLE Mutant Colon Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03827044
- Phase: PHASE3
- Status: TERMINATED
- Sponsor: Royal Marsden NHS Foundation Trust
- Conditions: POLE Exonuclease Mutant Colon Cancer; Microsatellite Instability; Stage III Colon Cancer
- Interventions: Avelumab
- Enrollment: 30
- Primary outcome: Primary End point: Disease Free survival

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 3

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=polem-nct03827044